Fenton SE - Search Results

1

Epidemiology, mutational landscape and staging of hepatocellular carcinoma.

Fenton SE, Burns MC, Kalyan A. Fenton SE, et al. Chin Clin Oncol. 2021 Feb;10(1):2. doi: 10.21037/cco-20-162. Chin Clin Oncol. 2021. PMID: 33541087 Free article. Review.

2

Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?

Hussain M, Carducci MA, Clarke N, Fenton SE, Fizazi K, Gillessen S, Jacene H, Morris MJ, Saad F, Sartor O, Taplin ME, Vapiwala N, Williams S, Sweeney C. Hussain M, et al. Among authors: fenton se. J Clin Oncol. 2022 Sep 10;40(26):3011-3014. doi: 10.1200/JCO.22.00208. Epub 2022 Apr 19. J Clin Oncol. 2022. PMID: 35439030 No abstract available.

3

Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma.

Fenton SE, VanderWeele DJ. Fenton SE, et al. Front Oncol. 2023 Jan 4;12:1069356. doi: 10.3389/fonc.2022.1069356. eCollection 2022. Front Oncol. 2023. PMID: 36686762 Free PMC article. Review.

4

First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature.

Weiner AB, Siebert AL, Fenton SE, Abida W, Agarwal N, Davis ID, Dorff TB, Gleave M, James ND, Poon DMC, Suzuki H, Sweeney CJ. Weiner AB, et al. Among authors: fenton se. Eur Urol Oncol. 2022 Aug;5(4):377-387. doi: 10.1016/j.euo.2022.04.009. Epub 2022 May 28. Eur Urol Oncol. 2022. PMID: 35641398 Review.

5

Emerging growth factor receptor antagonists for the treatment of advanced melanoma.

Fenton SE, Sosman JA, Chandra S. Fenton SE, et al. Expert Opin Emerg Drugs. 2017 Jun;22(2):165-174. doi: 10.1080/14728214.2017.1336537. Expert Opin Emerg Drugs. 2017. PMID: 28562096 Review.

6

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors.

Patrinely JR Jr, McGuigan B, Chandra S, Fenton SE, Chowdhary A, Kennedy LB, Mooradian MJ, Palmeri M, Portal D, Horst SN, Scoville EA, Long GV, Shi C, Mehnert JM, Sullivan RJ, Salama AK, Sosman JA, Menzies AM, Johnson DB. Patrinely JR Jr, et al. Among authors: fenton se. Oncoimmunology. 2021 Feb 8;10(1):1875639. doi: 10.1080/2162402X.2021.1875639. Oncoimmunology. 2021. PMID: 33628621 Free PMC article.

7

PARP Inhibition in Advanced Prostate Cancer.

Fenton SE, Chalmers ZR, Hussain M. Fenton SE, et al. Cancer J. 2021 Nov-Dec 01;27(6):457-464. doi: 10.1097/PPO.0000000000000560. Cancer J. 2021. PMID: 34904808 Review.

8

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.

Fenton SE, Sosman JA, Chandra S. Fenton SE, et al. Cancer Drug Resist. 2019 Sep 19;2(3):744-761. doi: 10.20517/cdr.2019.28. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582566 Free PMC article. Review.

9

Type I and II Interferons in the Anti-Tumor Immune Response.

Fenton SE, Saleiro D, Platanias LC. Fenton SE, et al. Cancers (Basel). 2021 Mar 2;13(5):1037. doi: 10.3390/cancers13051037. Cancers (Basel). 2021. PMID: 33801234 Free PMC article. Review.

10

Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors.

Fenton SE, Zannikou M, Ilut L, Fischietti M, Ji C, Oku CV, Horvath CM, Le Poole IC, Bosenberg M, Bartom ET, Kocherginsky M, Platanias LC, Saleiro D. Fenton SE, et al. Mol Cancer Res. 2023 Apr 1;21(4):332-344. doi: 10.1158/1541-7786.MCR-22-0684. Mol Cancer Res. 2023. PMID: 36573964 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

130 results

Search Page